Abstract
This paper is a focused review of our recent efforts to produce multi-nuclear platinum anti-cancer complexes that preferentially target adenine residues in DNA. Multi-nuclear platinum complexes, like cisplatin, predominantly form covalent adducts with guanine bases; however, controlling the pre-covalent binding association of the metal complex may modify this preference. NMR experiments, using oligonucleotides, indicate that multi-nuclear complexes linked by flexible diaminoalkanes will pre-associate in the DNA minor groove at A/T rich regions. Despite this pre-covalent binding preference, these complexes still predominantly covalently bind guanine residues. However, using 4,4ââ"šÂ¬Ã‚²-dipyrazolylmethane (dpzm) as a linking ligand produces a dinuclear platinum complex, trans-[{PtCl(NH3)2}2μ-dpzm]2+, that covalently binds DNA with a preference for adenine bases. In vitro transcription assays also demonstrate that the dpzm-based complex covalently binds within an A/T rich region of the 512 base-pair segment of DNA used for the study.
Original language | English |
---|---|
Number of pages | 7 |
Journal | Journal of Inorganic Biochemistry |
Publication status | Published - 2004 |
Keywords
- DNA adducts
- DNA-ligand interactions
- cancer
- chemical carcinogenesis
- chemotherapy
- cisplatin